Trastuzumab Deruxtecan in Patients with HER2+ mCRC: The DESTINY-CRC01 Trial

Opinion
Video

Dr Stacy A. Cohen discusses the DESTINY-CRC01 trial investigating trastuzumab deruxtecan in patients with colorectal cancer, specifically addressing the use of a targeted therapy for HER2 in colorectal cancer patients, highlighting the importance of prior therapy history and optimal dosage to balance efficacy and toxicity.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Hydration and a healthy, well-balanced diet may mitigate fatigue among patients undergoing treatment for cancer.
Related Content
A Variety of Treatment Options Are Becoming Available in CRC

A Variety of Treatment Options Are Becoming Available in CRC

ONCOLOGY Staff
September 9th 2025
Article
Geraldine O’Sullivan Coyne, MD, MRCPI, PhD, discusses how the START center may expand access to novel therapies for patients who reside in a community.

START Center Aims to Bring New Cancer Treatments, Trials to the Community

Geraldine O’Sullivan Coyne, MD, MRCPI, PhD
September 9th 2025
Podcast
Cabozantinib plus nivolumab and ipilimumab appears to improve progression-free survival vs cabozantinib alone among patients with metastatic soft-tissue sarcoma in a phase 2 trial.

Cabozantinib Combo Yields Disease Control in Metastatic Soft Tissue Sarcoma

Brielle Benyon
September 9th 2025
Article
1 expert in this video

Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025

Steven Finkelstein, MD, DABR, FACRO
September 9th 2025
Podcast